You just read:

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

News provided by

Daiichi Sankyo, Inc.

Nov 07, 2016, 08:00 ET